ADXN (ADXN) Stock Price & Analysis
ADXN (ADXN) rose 6.31% to USD 6.23 as of June 10, 2026 at 10:55 UTC, according to Nexqual real-time market data.
ADXN last closed at USD 5.86; the session ranged USD 6.23–6.23 on volume of 535 shares. Market capitalization is $7.89M, with a 52-week range of USD 5.41–12.05 (NCM). Source: Nexqual, June 10, 2026 at 10:55 UTC.
Key Statistics (as of June 10, 2026 at 10:55 UTC)
| Price | USD 6.23 |
|---|---|
| Change | ▲ 6.31% (up) |
| Previous Close | USD 5.86 |
| Open | USD 6.22 |
| Day Range | USD 6.23 – 6.23 |
| 52-Week Range | USD 5.41 – 12.05 |
| Volume | 535 shares |
| Market Cap | $7.89M |
| Exchange | NCM |
Technical Analysis (ADXN)
Nexqual's technical model rates ADXN "SELL" based on 2 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 10:55 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 33.34 (neutral) |
| vs SMA50 | Below (USD 6.68) |
| MACD | -0.17 (negative) |
Analyst Ratings (ADXN)
Wall Street analysts rate ADXN "None", per Nexqual as of June 10, 2026 at 10:55 UTC.
| Consensus Rating | None |
|---|
Earnings (ADXN)
Source: Nexqual, June 10, 2026 at 10:55 UTC.
Financials & Fundamentals (ADXN)
| Total Revenue | $172,860 |
|---|---|
| Revenue Growth (YoY) | +949.70% |
| Gross Margin | -288.55% |
| Operating Margin | -4922.70% |
| Profit Margin | +0.00% |
| ROE | -94.75% |
| Debt / Equity | 0.73 |
| Current Ratio | 1.4 |
| Total Cash | $1.64M |
| Total Debt | $34,688 |
| Free Cash Flow | $-1.27M |
Source: Nexqual, June 10, 2026 at 10:55 UTC.
Financial Health Score (ADXN)
Nexqual rates ADXN's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 10:55 UTC.
| Growth | Critical — Revenue -75% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $2M cash, no debt |
| Cash Flow | Weak — FCF negative: -$1M, burning cash |
| Efficiency | Critical — ROE -95%, ROA -20.6% |
Ownership (ADXN)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.05% |
| Shares Outstanding | 1.27M |
| Float | 1.03M |
| Short % of Float | +0.46% |
Source: Nexqual, June 10, 2026 at 10:55 UTC.
Leadership (ADXN)
ADXN is led by Timothy Mark Dyer (age 57), Co-Founder, CEO & Director, per Nexqual as of June 10, 2026 at 10:55 UTC.
| Co-Founder, CEO & Director | Timothy Mark Dyer (age 57) |
|---|---|
| Chief Medical Officer & Director | Roger G. Mills (age 68) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LIXT | Lixte Biotechnology Holdings, I | USD 6.87 | ▼ 1.86% |
| AFIB | Acutus Medical Inc. | USD 0 | ▲ 0% |
| DRMA | Dermata Therapeutics, Inc. | USD 1.2 | ▲ 1.69% |
| KZIA | Kazia Therapeutics Limited | USD 11.42 | ▲ 3.91% |
| BCDA | BioCardia, Inc. | USD 0.86 | ▼ 16.5% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 10:55 UTC. This page is informational and not investment advice.